IPSEN, OOO
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1929-01-01
- Employees
- 5.7K
- Market Cap
- $9.8B
- Website
- https://www.ipsen.com/
Efficacy, Safety and Tolerability of a New Bowel Cleansing Preparation (BLI800) in Adult Subjects Undergoing Colonoscopy
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2019-05-30
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 297
- Registration Number
- NCT03562884
- Locations
- 🇨🇳
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China
🇨🇳Zhong Shan Hospital, Shanghai, China
🇨🇳Peking Union Medical College Hospital, Beijing, China
Perception of Information and Quality of Life in Neuroendocrine Tumour on Lanreotide Autogel
- Conditions
- Neuroendocrine Tumors
- First Posted Date
- 2018-06-19
- Last Posted Date
- 2020-08-28
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 115
- Registration Number
- NCT03562091
- Locations
- 🇫🇷
Ipsen Central Contact, Paris, France
Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.
- Conditions
- Recurrent DiseaseBone CancerGastric CancerMetastatic TumoursAdvanced CancerPancreatic Ductal AdenocarcinomaColorectal CancerSquamous Cell Carcinoma of the Head and Neck
- Interventions
- First Posted Date
- 2018-05-15
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 14
- Registration Number
- NCT03525392
- Locations
- 🇳🇱
University Medical Center Groningen, Groningen, Netherlands
🇨🇭CHU Vaudois, Lausanne, Switzerland
🇨🇭Universitäts Spital Zürich, Zürich, Switzerland
Health Related Quality of Life and Multidimensional Evaluations of Prostate Cancer Subjects Aged ≥ 60 Years Initiating Gonadotropin-Releasing Hormone (GNRH) Agonist Therapy
- Conditions
- Prostate Cancer
- Interventions
- Other: Data collection
- First Posted Date
- 2018-05-04
- Last Posted Date
- 2020-04-30
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 831
- Registration Number
- NCT03516110
- Locations
- 🇫🇷
Ipsen Central Contact, Paris, France
Study to Compare a Dose of Telotristat Etiprate in Subjects With Renal Impairment With Matched Subjects With Normal Renal Function
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2020-04-08
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 16
- Registration Number
- NCT03442725
- Locations
- 🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Germany
🇲🇩ARENSIA Exploratory Medicine Phase I Unit, Republican Clinical Hospital, Chisinau, Moldova, Republic of
🇧🇪A.T.C. s.a., Clinical Pharmacology Unit, CHU Sart-Tilman, Liège, Belgium
Validation of the Spasticity Related Quality of Life Questionnaire
- Conditions
- Spasticity, Muscle
- Interventions
- Other: Data collection
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2019-09-30
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 104
- Registration Number
- NCT03442660
- Locations
- 🇬🇧
Mid Yorkshire Hospitals NHS Trust, Dewsbury Hospital, Dewsbury, United Kingdom
🇬🇧City Hospitals Sunderland NHS Foundation Trust Research and Innovation Education Centre, Sunderland, United Kingdom
🇬🇧Hull and East Yorkshire NHS Trust, Castle Hill Hospital, Cottingham, United Kingdom
Non-interventional Study of Cabozantinib in Adults With Advanced Renal Cell Carcinoma
- Conditions
- Renal Cell Carcinoma
- Interventions
- Other: Data collection
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2022-08-15
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 689
- Registration Number
- NCT03419572
- Locations
- 🇦🇹
Kepler University Hospital - Urology, Linz, Austria
🇦🇹Universitatsklinikum fur Urologie und Andrologie, Salzburg, Austria
🇧🇪Imelda Ziekenhuis, Bonheiden, Belgium
Study to Compare the Oestradiol Suppression, Clinical Efficacy and Safety of Two Formulations of Triptorelin (Triptorelin Pamoate PR 3-month and Triptorelin Acetate PR 1-month) in Chinese Subjects With Endometriosis
- Conditions
- Endometriosis
- Interventions
- First Posted Date
- 2017-07-27
- Last Posted Date
- 2021-10-14
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 300
- Registration Number
- NCT03232281
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, China
🇨🇳Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
🇨🇳The First Affiliated Hospital of Dalian Medical University, Dalian, China
Study to Evaluate the Use of Resources and the Costs Associated With Carcinoid Syndrome (CS) in Patients With NETs in Spain
- Conditions
- Neuroendocrine Tumors
- Interventions
- Other: Data collection
- First Posted Date
- 2017-07-18
- Last Posted Date
- 2018-12-21
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 142
- Registration Number
- NCT03220087
- Locations
- 🇪🇸
Hospital General Univ. de Elche, Alicante, Spain
🇪🇸ICO Badalona, Badalona, Spain
🇪🇸Hospital Clínico y Provincial de Barcelona, Barcelona, Spain
To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
- Conditions
- Gastro-Enteropancreatic Neuroendocrine Tumor
- Interventions
- Drug: Satoreotide trizoxetan 5-20μgDrug: Satoreotide trizoxetan 30-45μg
- First Posted Date
- 2017-07-18
- Last Posted Date
- 2021-01-14
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 29
- Registration Number
- NCT03220217
- Locations
- 🇦🇹
Medical University of Innsbruck, Innsbruck, Austria
🇦🇹University Clinic for Radiology and Nuclear Medicine, Vienna, Austria
🇺🇸UCLA Medical Center, Los Angeles, California, United States